Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Pareto8020on Mar 07, 2021 12:39pm
171 Views
Post# 32738833

RE:This morning tweet

RE:This morning tweetRemember the 4% clinical trial is already being sponsored by a major pharma company so once they see the results (combined with the existing info on the 2%) they could be trying to snap up the exclusive rights for the 4% formulation.  Keep in mind exclusive rights = big cheque they'll have to write.  And you are right there will likely be lots more announcements on the 2% as other major players want the new gold standard to replace the banned substance that was previously used in their formulations. 

Plus any day the Phase I and Animal Contract news could be hitting the wires.  The Phase I (if they are positive which all indications point to a big yes) alone should cause an upwards evaluation of the shareprice given the reducted risk on top of another milestone payment rolling into SBM.  Then if they can announce the animal contract with two major players that should really send things into the stratosphere. 

Feels like the waiting and waiting and watching management stumble their way to commercialization and revenue is finally paying off and should be an interesting ride once the wave of news hits.  GLTA!!

 
<< Previous
Bullboard Posts
Next >>